In our cohort, the rates of gastric cancers positive for E-cadherin, Ki67, VEGFR2 and EGFR expressions were 34.3% (35/102), 51.5% (70/136), 47.7% (63/132) and 32.8% (44/134), respectively. This evidence concerns the gene EGFR and gastric cancer.